Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508

Joseph I. Clark,J. Moon,L. Hutchins,J. Sosman,W. Kast,D. D. Da Silva,P. Liu,John A Thompson,L. Flaherty,V. Sondak
DOI: https://doi.org/10.1002/cncr.24739
IF: 6.9209
2010-01-15
Cancer
Abstract:In limited institution phase 2 studies, thalidomide and temozolomide has yielded response rates (RRs) up to 32% for advanced melanoma, leading to the use of this combination as “standard” by some. We conducted a multicenter phase 2 trial to better define the clinical efficacy of thalidomide and temozolomide and the immune modulatory effects of thalidomide, when combined with temozolomide, in patients with metastatic melanoma.
What problem does this paper attempt to address?